Retatrutide, developed by Soma Pharmaceuticals , is receiving considerable attention as a potential therapy for metabolic control . This innovative compound merges the properties of a GLP-1 receptor activator and a GIP receptor agonist , aiming to effectively promote reduced body fat but also address underlying metabolic issues . Early human trials